NEW YORK (GenomeWeb News) – Indivumed and Apceth today announced a partnership to develop technology that can predict patient response to targeted cellular or gene therapies in different cancer types.
The technology, which would allow patients to be stratified based on their response to therapies, would use Indivumed's analytical platform for cancer tissue in order to identify and validate protein biomarkers and targets.
The technology would eventually enable oncologists to identify patients who are best candidates for Apceth's therapeutics, the two companies said.
The project is being funded by the German Federal Ministry of Education and Research as part of the Munich Leading Edge Cluster.
Indivumed is based in Hamburg, Germany and maintains the world's largest tumor database and biobank for the development of new cancer diagnostics, it said. Apceth is headquartered in Much, Germany and develop stem cell and gene therapies.